Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Folia Microbiol (Praha) ; 65(2): 245-264, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31773556

RESUMO

The prebiotics and probiotics market is constantly growing due to the positive effects of its consumption on human health, which extends beyond the digestive system. In addition, the synbiotic products market is also expanding due to the synergistic effects between pre- and probiotics that provide additional benefits to consumers. Pre- and probiotics are being evaluated for their effectiveness to treat and prevent infectious diseases in other parts of the human body where microbial communities exist. This review examines the scientific data related to the effects of pre- and probiotics on the treatment of diseases occurring in the skin, female urogenital tract, and respiratory tract. The evidence suggests that probiotics consumption can decrease the presence of eczema in children when their mothers have consumed probiotics during pregnancy and lactation. In women, probiotics consumption can effectively prevent recurrent urinary tract infections. The consumption of synbiotic products can reduce respiratory tract infections and their duration and severity. However, the outcomes of the meta-analyses are still limited and not sufficiently conclusive to support the use of probiotics to treat infectious diseases. This is largely a result of the limited number of studies, lack of standardization of the studies, and inconsistencies between the reported results. Therefore, it is advisable that future studies consider these shortcomings and include the evaluation of the combined use of pre- and probiotics.


Assuntos
Prebióticos/administração & dosagem , Probióticos/administração & dosagem , Sistema Respiratório/efeitos dos fármacos , Pele/efeitos dos fármacos , Sistema Urogenital/efeitos dos fármacos , Feminino , Humanos , Masculino , Sistema Respiratório/microbiologia , Pele/microbiologia , Sistema Urogenital/microbiologia
2.
Environ Toxicol ; 31(12): 1740-1750, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26443714

RESUMO

Substances that mimic endogenous hormones may alter the cell signaling that govern prostate development and predispose it to developing lesions in adult and senile life. Bisphenol A is able to mimic estrogens, and studies have demonstrated that low levels of exposure to this compound have caused alterations during prostate development. The aim of this study was to describe the prostate development in both male and female neonatal gerbils in normal conditions and under exposure to BPA during intrauterine life, and also to analyze whether the effects of intrauterine exposure to BPA remain in adulthood. Morphological, stereological, three-dimensional reconstruction, and immunohistochemical methods were employed. The results demonstrated that in 1-day-old normal gerbils, the female paraurethral glands and the male ventral lobe are morphologically similar, although its tissue components-epithelial buds (EB), periurethral mesenchyme (PeM), paraurethral mesenchyme (PaM) or ventral mesenchymal pad (VMP), and smooth muscle (SM)-have presented different immunolabeling pattern for androgen receptor (AR), and for proliferating cell nuclear antigen (PCNA). Moreover, we observed a differential response of male and female prostate to intrauterine BPA exposure. In 1-day-old males, the intrauterine exposure to BPA caused a decrease of AR-positive cells in the PeM and SM, and a decrease of the proliferative status in the EB. In contrast, no morphological alterations were observed in ventral prostate of adult males. In 1-day-old females, BPA exposure promoted an increase of estrogen receptor alpha (ERα) positive cells in PeM and PaM, a decrease of AR-positive cells in EB and PeM, besides a reduction of cell proliferation in EB. Additionally, the adult female prostate of BPA-exposed animals presented an increase of AR- and PCNA-positive cells. These results suggest that the prostate of female gerbils were more susceptible to the intrauterine BPA effects, since they became more proliferative in adult life. © 2015 Wiley Periodicals, Inc. Environ Toxicol 31: 1740-1750, 2016.


Assuntos
Compostos Benzidrílicos/toxicidade , Disruptores Endócrinos/toxicidade , Fenóis/toxicidade , Sistema Urogenital/efeitos dos fármacos , Fatores Etários , Animais , Animais Recém-Nascidos , Proliferação de Células/efeitos dos fármacos , Epitélio/efeitos dos fármacos , Epitélio/metabolismo , Receptor alfa de Estrogênio/metabolismo , Feminino , Gerbillinae , Masculino , Exposição Materna/efeitos adversos , Mesoderma/efeitos dos fármacos , Mesoderma/metabolismo , Antígeno Nuclear de Célula em Proliferação/metabolismo , Próstata/citologia , Próstata/efeitos dos fármacos , Próstata/embriologia , Próstata/crescimento & desenvolvimento , Receptores Androgênicos/metabolismo , Fatores Sexuais , Sistema Urogenital/citologia , Sistema Urogenital/embriologia , Sistema Urogenital/crescimento & desenvolvimento
3.
Menopause ; 22(7): 786-96, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25423325

RESUMO

OBJECTIVE: Treatment of menopausal symptoms by compounds with tissue-selective estrogen agonist/antagonist effects, often called selective estrogen receptor modulators, has been researched as an alternative to the use of estrogen therapy. These structurally diverse molecules elicit tissue-dependent responses in hormone-responsive tissues and organs, exhibiting variations in estrogenic activity in preclinical models of postmenopausal reproductive tissues that may improve postmenopausal women's health (eg, prevention and treatment of breast cancer, osteoporosis, and vulvar and vaginal atrophy). METHODS: This literature review investigates whether preclinical data predicted the clinical effects of ospemifene on female reproductive and urinary tract tissues and compares these findings with the specific vaginal effects of other estrogen receptor agonists/antagonists (tamoxifen, raloxifene, and bazedoxifene) in preclinical and clinical studies. Lasofoxifene, although not currently available, is included because of its unique effects on vaginal tissue. RESULTS: The response of endometrial and vaginal tissues to estrogen receptor agonists/antagonists can be differentiated using transvaginal ultrasound, endometrial histopathology, cytologic examination of vaginal smears, assessment of physical changes in the vagina, and relief of symptoms associated with vulvar and vaginal atrophy (such as dyspareunia). CONCLUSIONS: Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists (eg, tamoxifen, raloxifene, and bazedoxifene) with no short-term concerns about endometrial safety (based on endometrial hyperplasia, carcinoma, endometrial spotting, and endometrial bleeding).


Assuntos
Antagonistas de Estrogênios/farmacologia , Menopausa/efeitos dos fármacos , Tamoxifeno/análogos & derivados , Pesquisa Translacional Biomédica , Sistema Urogenital/efeitos dos fármacos , Feminino , Doenças Urogenitais Femininas/tratamento farmacológico , Humanos , Tamoxifeno/farmacologia
4.
Menopause ; 22(7): 741-9, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25423326

RESUMO

OBJECTIVE: This study aims to compare the effects of a soy-based dietary supplement, low-dose hormone therapy (HT), and placebo on the urogenital system in postmenopausal women. METHODS: In this double-blind, randomized, placebo-controlled trial, 60 healthy postmenopausal women aged 40 to 60 years (mean time since menopause, 4.1 y) were randomized into three groups: a soy dietary supplement group (90 mg of isoflavone), a low-dose HT group (1 mg of estradiol plus 0.5 mg of norethisterone), and a placebo group. Urinary, vaginal, and sexual complaints were evaluated using the urogenital subscale of the Menopause Rating Scale. Vaginal maturation value was calculated. Transvaginal sonography was performed to evaluate endometrial thickness. Genital bleeding pattern was assessed. Statistical analysis was performed using χ(2) test, Fisher's exact test, paired Student's t test, Kruskal-Wallis test, Kruskal-Wallis nonparametric test, and analysis of variance. For intergroup comparisons, Kruskal-Wallis nonparametric test (followed by Mann-Whitney U test) was used. RESULTS: Vaginal dryness improved significantly in the soy and HT groups (P = 0.04). Urinary and sexual symptoms did not change with treatment in the three groups. After 16 weeks of treatment, there was a significant increase in maturation value only in the HT group (P < 0.01). Vaginal pH decreased only in this group (P < 0.01). There were no statistically significant differences in endometrial thickness between the three groups, and the adverse effects evaluated were similar. CONCLUSIONS: This study shows that a soy-based dietary supplement used for 16 weeks fails to exert estrogenic action on the urogenital tract but improves vaginal dryness.


Assuntos
Suplementos Nutricionais , Estradiol/farmacologia , Isoflavonas/farmacologia , Noretindrona/farmacologia , Pós-Menopausa/efeitos dos fármacos , Proteínas de Soja/farmacologia , Sistema Urogenital/efeitos dos fármacos , Adulto , Método Duplo-Cego , Terapia de Reposição de Estrogênios/métodos , Feminino , Humanos , Pessoa de Meia-Idade , Fitoterapia , Pós-Menopausa/fisiologia , Ultrassonografia , Sistema Urogenital/diagnóstico por imagem , Doenças Vaginais/tratamento farmacológico
5.
Ther Drug Monit ; 28(2): 175-9, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16628127

RESUMO

The concentrations of lopinavir and ritonavir in seminal and blood plasma and the seminal human immunodeficiency virus (HIV) viral load were quantified by HPLC and the Nuclisens assay, respectively, in a cross-sectional study of 16 HIV-1-infected Brazilian men under stable treatment with a lopinavir/ritonavir containing antiretroviral regimen. Semen and blood samples were collected on 2 occasions: at 6 to 60 minutes before ("trough"), and 5 to 6 hours after ("peak") ingestion of regular doses of lopinavir/ritonavir. Median seminal lopinavir levels were 120.6 ng/mL (range, <20-1481.8 ng/mL) and 233.1 ng/mL (range, 48.4-1133.4 ng/mL) at trough and peak points, respectively. The corresponding values for ritonavir were 9.2 ng/mL (range, <5-47 ng/mL) and 17.1 ng/mL (range, 6.6-66.7 ng/mL). The median concentrations of lopinavir and ritonavir in semen were, respectively, 1.9% to 3% and 3.7% to 4.4% of those measured in blood plasma samples collected within 30 minutes. HIV-1 viral load was detectable in the semen of 2 and in the blood of 6 of 16 patients. These results may have implications for drug-resistant HIV-1 evolution and transmission.


Assuntos
Infecções por HIV/tratamento farmacológico , Pirimidinonas/farmacocinética , Ritonavir/farmacocinética , Sistema Urogenital/metabolismo , Disponibilidade Biológica , Brasil , Estudos Transversais , Infecções por HIV/sangue , Infecções por HIV/virologia , Inibidores da Protease de HIV/sangue , Inibidores da Protease de HIV/farmacocinética , Inibidores da Protease de HIV/uso terapêutico , HIV-1/efeitos dos fármacos , HIV-1/crescimento & desenvolvimento , Humanos , Lopinavir , Masculino , Pirimidinonas/sangue , Pirimidinonas/uso terapêutico , Análise de Regressão , Ritonavir/sangue , Ritonavir/uso terapêutico , Sêmen/química , Sêmen/efeitos dos fármacos , Fatores de Tempo , Sistema Urogenital/efeitos dos fármacos , Carga Viral
7.
Cad Saude Publica ; 18(2): 495-504, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-11923891

RESUMO

Endocrine disruption is a hypothesis of common mode of action that may define a set of structurally varied chemicals, both natural and synthetic. Their common mode of action may suggest that they produce or contribute to similar toxic effects, although this has been difficult to demonstrate. Insights from developmental biology suggest that development of hormone sensitive systems, such as the brain and the genitourinary tract, may be particularly sensitive to EDCs. Because these systems are both organized and later activated by hormones, the brain and vagina may be valuable model systems to study the toxicity of EDCs in females and to elucidate mechanisms whereby early exposures appear to affect long term function.


Assuntos
Sistema Endócrino/efeitos dos fármacos , Exposição Ambiental/efeitos adversos , Estrogênios/efeitos adversos , Sistema Urogenital/efeitos dos fármacos , Animais , Encéfalo/efeitos dos fármacos , Desenvolvimento Embrionário e Fetal/efeitos dos fármacos , Sistema Endócrino/fisiopatologia , Estrogênios/genética , Feminino , Humanos , Masculino , Transdução de Sinais , Vagina/efeitos dos fármacos
8.
Med. interna Méx ; 13(2): 82-7, mar.-abr. 1997. ilus
Artigo em Espanhol | LILACS | ID: lil-227005

RESUMO

El tabaquismo tiene múltiples efectos sobre el aparato genitourinario. El más conocido es su efecto carcinogénico, pues es una causa importante de cáncer de riñón, vejiga, pelvis renal y ureteros. Los agentes causales son las aminas aromáticas del tabaco, y parece existir una susceptibilidad variable a estas sustancias que depende del genotipo de cada persona. En el sexo masculino el tabaquismo se ha relacionado con la impotencia sexual, infertilidad, desbalances hormonales y teratogenicidad. También se han observado alteraciones en el control del balance de agua, así como un mayor deterioro de algunos padecimientos glomerulares


Assuntos
Humanos , Albuminas/efeitos dos fármacos , Nefropatias Diabéticas/complicações , Albumina Sérica , Fumar/efeitos adversos , Fumar/epidemiologia , Fumar/genética , Neoplasias da Bexiga Urinária/etiologia , Neoplasias da Bexiga Urinária/mortalidade , Sistema Urogenital/efeitos dos fármacos , Infertilidade Masculina , Nefropatias/etiologia , Mortalidade , Neoplasias
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA